Avaliação da expressão de syndecan-4 e de seu papel como biomarcador na cardiomiopatia chagásica crônica.

Submitted by Ana Maria Fiscina Sampaio ([email protected]) on 2017-04-24T19:26:52Z No. of bitstreams: 2 Ticiana Ferreira Larocca Avaliação da expressão....pdf: 15793721 bytes, checksum: a85f09b18bf960a9af5659e3a4854c73 (MD5) Ticiana Ferreira Larocca Avaliação da expressão....pdf: 15793721 bytes, checksum: a85f09b18bf960a9af5659e3a4854c73 (MD5)Approved for entry into archive by Ana Maria Fiscina Sampaio ([email protected]) on 2017-04-24T19:39:00Z (GMT) No. of bitstreams: 2 Ticiana Ferreira Larocca Avaliação da expressão....pdf: 15793721 bytes, checksum: a85f09b18bf960a9af5659e3a4854c73 (MD5) Ticiana Ferreira Larocca Avaliação da expressão....pdf: 15793721 bytes, checksum: a85f09b18bf960a9af5659e3a4854c73 (MD5)Made available in DSpace on 2017-04-24T19:39:00Z (GMT). No. of bitstreams: 2 Ticiana Ferreira Larocca Avaliação da expressão....pdf: 15793721 bytes, checksum: a85f09b18bf960a9af5659e3a4854c73 (MD5) Ticiana Ferreira Larocca Avaliação da expressão....pdf: 15793721 bytes, checksum: a85f09b18bf960a9af5659e3a4854c73 (MD5) Previous issue date: 2016CNPq. FAPESBFundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, BrasilINTRODUÇÃO: A cardiomiopatia chagásica crônica (CCC), doença de elevada morbimortalidade, associada à grave disfunção ventricular e a arritmias cardíacas, caracteriza-se histologicamente por intensa reação inflamatória multifocal, com pronunciada fibrose miocárdica. Diante da ausência de uma terapia eficaz para os pacientes com as formas mais graves da doença, torna-se crucial a descoberta de biomarcadores que possam identificar pacientes em estágios mais precoces, sob risco mais elevado para a progressão da doença. Neste contexto, surge a syndecan-4, uma glicoproteína transmembrana associada à inflamação e fibrose, cujos níveis estão aumentados em indivíduos com insuficiência cardíaca. OBJETIVO: Neste trabalho, avaliamos o padrão de expressão da syndecan-4 no tecido cardíaco de camundongos e de indivíduos com cardiomiopatia chagásica e a possível correlação entre a concentração sérica de syndecan-4 com grau de fibrose miocárdica e com fração de ejeção do ventrículo esquerdo em indivíduos com doença de Chagas. MÉTODOS: A expressão de syndecan-4 foi avaliada através da contagem de vasos positivos para esta proteína no coração de camundongos em diferentes momentos após a infecção com a cepa colombiana de T. cruzi, e em fragmentos de corações explantados de indivíduos com doença de Chagas, cardiomiopatia isquêmica (CMI) e cardiomiopatia dilatada idiopática (CMDI). Também foram determinados nestes tecidos o número de células inflamatórias e o percentual de fibrose miocárdica. Na segunda etapa do trabalho, foi desenvolvido um estudo clínico, no qual foram incluídos 56 indivíduos com doença de Chagas, 8 controles saudáveis e 8 pacientes com insuficiência cardíaca não-chagásica. A concentração sérica de syndecan-4 foi determinada por ELISA. RESULTADOS: Evidenciamos expressão de syndecan-4 principalmente nas células musculares lisas, tanto em corações de camundongos quanto em fragmentos de corações humanos. Não foi encontrada correlação entre a expressão de syndecan-4 e inflamação ou fibrose nos corações de indivíduos com CCC. Também comparamos a expressão de syndecan-4 de indivíduos com CCC, CMDI e CMI. Não foram observadas diferenças no número de vasos positivos para syndecan-4/mm2 quando comparados os três grupos de indivíduos (P = 0,466), tendo sido observada uma diferença estatisticamente significativa no número de células inflamatórias/mm2 (P = 0,035). No estudo clínico, não foram observadas diferenças nas concentrações de syndecan-4 de acordo com a presença ou ausência de fibrose miocárdica (P=0,386) ou entre as três formas de apresentação da doença de Chagas (P = 0,918). Do mesmo modo, não houve correlação entre fibrose miocárdica e syndecan-4 (r = 0,08, P = 0,567) ou entre fração de ejeção do ventrículo esquerdo e syndecan-4 (r = 0,02; P = 0,864). CONCLUSÃO: Apesar de a syndecan-4 estar expressa nos corações tanto de camundongos quanto de seres humanos com doença de Chagas, os nossos dados sugerem que, em sua forma solúvel, esta proteína não possa ser utilizada como biomarcador ou como preditor de fibrose miocárdica para este perfil de pacientes.INTRODUCTION: The hallmark of chronic Chagas cardiomyopathy (CCC) is the presence of a multifocal inflammatory reaction, which leads to myocardial fibrosis, often followed by ventricular dysfunction and arrhythmias. Syndecan-4 is a transmembrane glycoprotein associated with inflammation and fibrosis. Syndecan-4 levels are increased in subjects with heart failure and it has been proposed as a biomarker to predict cardiovascular events. The expression of syndecan-4 is increased in the hearts of mice chronically infected with Trypanosoma cruzi, suggesting a role of this protein in the pathogenesis of CCC. OBJETIVE: Here we aimed to evaluate the pattern of expression of syndecan-4 in heart tissue of mice and subjects with Chagas cardiomyopathy, and to correlate with the degree of inflammation and fibrosis, as well as to determine the correlation of syndecan-4 serum concentration with the degree of myocardial fibrosis and with left ventricular ejection fraction in subjects with Chagas disease. METHODS: We assessed the expression of syndecan-4, inflammation and fibrosis in the hearts of mice at different time points after infection with T. cruzi Colombian strain, and in fragments of explanted hearts from subjects with Chagas disease, ischemic cardiomyopathy (ICM) and idiopathic dilated cardiomyopathy (idDCM). The clinical study comprised 56 subjects with Chagas disease, 8 healthy controls and 8 subjects with non-Chagas heart failure, who underwent clinical and complementary assessments. Serum concentration of syndecan-4 was determined by enzymelinked immunosorbent assay (ELISA). RESULTS: Confocal microscopy analysis showed syndecan-4 expression mainly by smooth muscle in blood vessels of mouse heart and of fragments of explanted human hearts. No correlation between syndecan-4 expression and inflammation or fibrosis was found in the hearts from subjects with CCC. We also compared the expression of syndecan-4 of subjects with CCC, idDCM and ICM. No differences in the number of syndecan-4 positive vessels/mm2 were found comparing the three subject groups (P=0.466), whereas a statistically significant difference in inflammation was seen (P=0.035). Additionally, no correlation between syndecan-4 and fibrosis or inflammatory cells was found. In the clinical study, no differences were observed in syndecan-4 concentrations according to the presence or absence of myocardial fibrosis (P=0.386) and among different forms of Chagas disease (P=0.918). Moreover, no correlation was found either between myocardial fibrosis and syndecan-4 (r=0.08; P=0.567) or between left ventricular ejection fraction and syndecan-4 (r =0.02; P=0.864). CONCLUSION: Although syndecan-4 is expressed in the hearts of both mice and humans with Chagas disease, our data do not suggest that this protein, in its soluble form, can be used as a biomarker or as a predictor of myocardial fibrosis for this setting of subjects

Optimization of oncological 18F-FDG PET/CT imaging based on a multiparameter analysis

Submitted by Ana Maria Fiscina Sampaio ([email protected]) on 2016-05-12T19:05:36Z No. of bitstreams: 1 Menezes VO Optimization....pdf: 2748103 bytes, checksum: 8446733e75e4b2c0c251d96a9269ffdd (MD5)Approved for entry into archive by Ana Maria Fiscina Sampaio ([email protected]) on 2016-05-12T19:23:57Z (GMT) No. of bitstreams: 1 Menezes VO Optimization....pdf: 2748103 bytes, checksum: 8446733e75e4b2c0c251d96a9269ffdd (MD5)Made available in DSpace on 2016-05-12T19:23:57Z (GMT). No. of bitstreams: 1 Menezes VO Optimization....pdf: 2748103 bytes, checksum: 8446733e75e4b2c0c251d96a9269ffdd (MD5) Previous issue date: 2016São Rafael Hospital. Nuclear Medicine Department. Salvador, BA, Brasil / Universidade Federal de Pernambuco. Hospital das Clínicas. Nuclear Medicine Department. Recife, PE, BrasilSão Rafael Hospital. Nuclear Medicine Department. Salvador, BA, Brasil / Hospital das Clínicas da Universidade Federal de Bahia/Ebserh, Salvador 40110-060, BrazilSão Rafael Hospital. Nuclear Medicine Department. Salvador, BA, Brasil / Hospital Universitário Professor Alberto Antunes/Ebserh. Nuclear Medicine Department. Maceió, AL, BrasilUniversidade Federal de Sergipe. Department of Physics. São Cristóvão, SE, BrasilYale University School of Medicine. Department of Diagnostic Radiology. New Haven, Connecticut / University of Pisa. School of Engineering. Pisa, ItalyFundación Centro Diagnóstico Nuclear, Buenos Aires, ArgentinaSão Rafael Hospital. Centro de Biotecnologia e Terapia Celular. Salvador, BA, BrasilSão Rafael Hospital. Centro de Biotecnologia e Terapia Celular. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, BrasilPurpose: This paper describes a method to achieve consistent clinical image quality in 18F-FDG scans accounting for patient habitus, dose regimen, image acquisition, and processing techniques. Methods: Oncological PET/CT scan data for 58 subjects were evaluated retrospectively to derive analytical curves that predict image quality. Patient noise equivalent count rate and coefficient of variation (CV) were used as metrics in their analysis. Optimized acquisition protocols were identified and prospectively applied to 179 subjects. Results: The adoption of different schemes for three body mass ranges (90 kg) allows improved image quality with both point spread function and ordered-subsets expectation maximization-3D reconstruction methods. The application of this methodology showed that CV improved significantly (p < 0.0001) in clinical practice. Conclusions: Consistent oncological PET/CT image quality on a high-performance scanner was achieved from an analysis of the relations existing between dose regimen, patient habitus, acquisition, and processing techniques. The proposed methodology may be used by PET/CT centers to develop protocols to standardize PET/CT imaging procedures and achieve better patient management and cost-effective operations

Transplantation of Adipose Tissue Mesenchymal Stem Cells in Experimental Chronic Chagasic Cardiopathy

BACKGROUND: Chagas disease, caused by the protozoan Trypanosoma cruzi, is a major cause of heart failure in Latin America. Tissue therapy has been investigated as a possible therapeutic option for patients with cardiovascular disease. OBJECTIVE: This study evaluated the effects of therapy with mesenchymal stem cells in an experimental model of chronic Chagasic cardiomyopathy. METHODS: C57BL/6 mice were infected with 1000 trypomastigotes from the Colombian strain of T. cruzi and, after six months of infection, were treated with mesenchymal human stem cells from adipose tissue (STAT) or with Dulbecco/Vogt modified Eagle's minimal essential medium - DMEM (control). The treated group received two intraperitoneal injections of STAT (1x10(6) cells/dose), with a month interval between the two doses. Before and after the first and second months of treatment, the chagasic and normal control animals underwent cardiopulmonary exercise testing and electrocardiography. All animals were sacrificed under anesthesia after two months of treatment for histopathological analysis of the heart. RESULTS: No improvement was observed in arrhythmias and cardiovascular function in the group of animals treated with STAT; however, sections of mice hearts in this group revealed a significant reduction in the number of inflammatory cells (p<0.0001) and areas of fibrosis (p<0.01) in comparison with chagasic animals treated with DMEM. CONCLUSION: Thus, it is concluded that administration of intraperitoneal STAT can reduce inflammation and fibrosis in the heart of mice chronically infected with T. cruzi; however, there were no effects on the cardiac function two months after transplantation

Assessment of speckle tracking strain predictive value for myocardial fibrosis in subjects with Chagas disease

Submitted by Ana Maria Fiscina Sampaio ([email protected]) on 2016-05-12T12:36:51Z No. of bitstreams: 1 Macedo CT Assessment....pdf: 661652 bytes, checksum: a14aaf455b6a4c89eef253f8b95079bc (MD5)Approved for entry into archive by Ana Maria Fiscina Sampaio ([email protected]) on 2016-05-12T12:51:06Z (GMT) No. of bitstreams: 1 Macedo CT Assessment....pdf: 661652 bytes, checksum: a14aaf455b6a4c89eef253f8b95079bc (MD5)Made available in DSpace on 2016-05-12T12:51:06Z (GMT). No. of bitstreams: 1 Macedo CT Assessment....pdf: 661652 bytes, checksum: a14aaf455b6a4c89eef253f8b95079bc (MD5) Previous issue date: 2015Hospital São Rafael. Departamento de Cardiologia. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, BrasilHospital São Rafael. Departamento de Cardiologia. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, BrasilHospital São Rafael. Departamento de Cardiologia. Salvador, BA, BrasilHospital São Rafael. Departamento de Cardiologia. Salvador, BA, BrasilHospital São Rafael. Departamento de Cardiologia. Salvador, BA, BrasilHospital São Rafael. Departamento de Cardiologia. Salvador, BA, BrasilHospital São Rafael. Departamento de Cardiologia. Salvador, BA, BrasilHospital São Rafael. Departamento de Cardiologia. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, BrasilHospital São Rafael. Departamento de Cardiologia. Salvador, BA, BrasilHospital São Rafael. Departamento de Cardiologia. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, BrasilBackground: One of the most challenging issues of chronic Chagas disease is to provide earlier detection of heart involvement. Two-dimensional speckle tracking (2-D ST) echocardiography, a new imagingmodalitywith useful applications in several cardiac diseases, has been validated for subjects with myocardial infarction against cardiac magnetic resonance (CMR). Here we hypothesize that the longitudinal global strain (LGS) has an incremental value to ejection fraction for predicting myocardial fibrosis in subjects with Chagas disease. Methods: This observational study comprised 58 subjectswith Chagas disease, confirmed by two positive serologic tests. All subjects underwent conventional Doppler echocardiogramplus speckle tracking strain, and cardiacmagnetic resonance. Results: The ROC curve analysis revealed that both LGS (area under the curve: 0.78, p=0.001) and ejection fraction (area under the curve: 0.82, p b 0.001)were significant predictors ofmyocardial fibrosis. Regarding the percentage of fibrosis, a high correlation was observed with both ejection fraction assessed by echocardiography (r =0.70, p b 0.001) and LGS (r = 0.64, p b 0.001). However, when adjusted through multiple linear regression, the LGS lost statistical significance as a predictor of myocardial fibrosis (p = 0.111). Conclusions: LGS has no incremental value to conventional ejection fractionmeasurement in the prediction ofmyocardial fibrosis in subjects with Chagas disease

Assessment of Galectin-3 Polymorphism in Subjects with Chronic Chagas Disease

Submitted by Ana Maria Fiscina Sampaio ([email protected]) on 2016-03-23T13:16:57Z No. of bitstreams: 1 Cruz GS Assessment....pdf: 409829 bytes, checksum: 769c74faa40f7a24344a6dc548381ea6 (MD5)Approved for entry into archive by Ana Maria Fiscina Sampaio ([email protected]) on 2016-03-23T13:35:11Z (GMT) No. of bitstreams: 1 Cruz GS Assessment....pdf: 409829 bytes, checksum: 769c74faa40f7a24344a6dc548381ea6 (MD5)Made available in DSpace on 2016-03-23T13:35:11Z (GMT). No. of bitstreams: 1 Cruz GS Assessment....pdf: 409829 bytes, checksum: 769c74faa40f7a24344a6dc548381ea6 (MD5) Previous issue date: 2015Hospital São Rafael. Centro de Biotecnologia e Terapia Celular. Salvador, BA, BrasilHospital São Rafael. Centro de Biotecnologia e Terapia Celular. Salvador, BA, BrasilHospital São Rafael. Centro de Biotecnologia e Terapia Celular. Salvador, BA, Brasil / Hospital São Rafael. Departamento de Cardiologia. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, BrasilHospital São Rafael. Centro de Biotecnologia e Terapia Celular. Salvador, BA, Brasil / Hospital São Rafael. Departamento de Cardiologia. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, BrasilHospital São Rafael. Departamento de Cardiologia. Salvador, BA, BrasilHospital São Rafael. Departamento de Cardiologia. Salvador, BA, BrasilHospital São Rafael. Departamento de Cardiologia. Salvador, BA, BrasilHospital São Rafael. Centro de Biotecnologia e Terapia Celular. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, BrasilHospital São Rafael. Centro de Biotecnologia e Terapia Celular. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, BrasilHospital São Rafael. Centro de Biotecnologia e Terapia Celular. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, BrasilBACKGROUND: Galectin-3, a ß-galactoside binding lectin, has been described as a mediator of cardiac fibrosis in experimental studies and as a risk factor associated with cardiovascular events in subjects with heart failure. Previous studies have evaluated the genetic susceptibility to Chagas disease in humans, including the polymorphisms of cytokine genes, demonstrating correlations between the genetic polymorphism and cardiomyopathy development in the chronic phase. However, the relationship between the galectin-3 single nucleotide polymorphism (SNP) and phenotypic variations in Chagas disease has not been evaluated. OBJECTIVE: The present study aimed to determine whether genetic polymorphisms of galectin-3 may predispose to the development of cardiac forms of Chagas disease. METHODS: Fifty-five subjects with Chagas disease were enrolled in this observational study. Real-time polymerase chain reaction (PCR) was used for genotyping the variants rs4644 and rs4652 of the galectin-3 gene. RESULTS: For the SNP rs4644, the relative risk for the cardiac form was not associated with the genotypes AA (OR = 0.79, p = 0.759), AC (OR = 4.38, p = 0.058), or CC (OR = 0.39, p = 0.127). Similarly, for the SNP rs4652, no association was found between the genotypes AA (OR = 0.64, p = 0.571), AC (OR = 2.85, p = 0.105), or CC (OR = 0.49, p = 0.227) and the cardiac form of the disease. CONCLUSION: Our results showed no association between the different genotypes for both SNPs of the galectin-3 gene and the cardiac form of Chagas disease

Evaluation of Galectin-3 as a Novel Biomarker for Chagas Cardiomyopathy

Submitted by Ana Maria Fiscina Sampaio ([email protected]) on 2017-11-23T12:50:45Z No. of bitstreams: 1 Rabelo MMN Evaluation of galectin-3....pdf: 140623 bytes, checksum: 3f19bd9f18869f4e4c812b28c9829fdf (MD5)Approved for entry into archive by Ana Maria Fiscina Sampaio ([email protected]) on 2017-11-23T13:01:55Z (GMT) No. of bitstreams: 1 Rabelo MMN Evaluation of galectin-3....pdf: 140623 bytes, checksum: 3f19bd9f18869f4e4c812b28c9829fdf (MD5)Made available in DSpace on 2017-11-23T13:01:55Z (GMT). No. of bitstreams: 1 Rabelo MMN Evaluation of galectin-3....pdf: 140623 bytes, checksum: 3f19bd9f18869f4e4c812b28c9829fdf (MD5) Previous issue date: 2017FAPESBHospital São Rafael. Department of Cardiology. Salvador, BA, Brasil / Escola Bahiana de Medicina e Saúde Pública. Salvador, BA, BrasilHospital São Rafael. Department of Cardiology. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil / Center for Biotechnology and Cell Therapy. Salvador, BA, BrasilHospital São Rafael. Department of Cardiology. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil / Center for Biotechnology and Cell Therapy. Salvador, BA, BrasilHospital São Rafael. Department of Cardiology. Salvador, BA, Brasil / Escola Bahiana de Medicina e Saúde Pública. Salvador, BA, BrasilFundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil / Center for Biotechnology and Cell Therapy. Salvador, BA, BrasilFundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil / Center for Biotechnology and Cell Therapy. Salvador, BA, BrasilHospital São Rafael. Clinical Diagnostics Laboratory. Salvador, BA, BrasilHospital São Rafael. Clinical Diagnostics Laboratory. Salvador, BA, BrasilCenter for Biotechnology and Cell Therapy. Salvador, BA, BrasilHospital São Rafael. Department of Cardiology. Salvador, BA, Brasil / Escola Bahiana de Medicina e Saúde Pública. Salvador, BA, BrasilFundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil / Center for Biotechnology and Cell Therapy. Salvador, BA, BrasilChagas cardiomyopathy has worse long-term outcomes than other cardiomyopathies. A biomarker strategy to refer subjects for noninvasive cardiac imaging may help in the early identification of cardiac damage in subjects with Chagas disease. Galectin-3 (Gal-3) is a mediator of cardiac fibrosis shown to be upregulated in animal models of decompensated heart failure. Here we assessed the correlation of Gal-3 with myocardial fibrosis in patients with Chagas disease. Methods: This study comprised 61 subjects with Chagas disease. All subjects underwent clinical assessments, Doppler echocardiography and magnetic resonance imaging. Plasmatic Gal-3 was determined by ELISA. Results: Delayed enhancement (DE) was identified in 37 of 61 subjects (64%). The total amount of myocardial fibrosis was 9.4% [interquartile interval (IQI): 2.4–18.4]. No differences were observed in Gal-3 concentration according to the presence or absence of myocardial fibrosis, with a median Gal-3 concentration of 11.7 ng/ml (IQI: 9.4–15) in subjects with DE versus 12.9 ng/ml (IQI: 9.2–14) in subjects without DE (p = 0.18). No correlation was found between myocardial fibrosis and Gal- 3 concentration (r = 0.098; p = 0.47). Conclusions: There is no correlation between the degree of myocardial fibrosis and the concentration of Gal-3 in subjects with Chagas diseas

Assessment of syndecan-4 expression in the hearts of Trypanosoma cruzi-infected mice and human subjects with chronic Chagas disease cardiomyopathy

Submitted by Ana Maria Fiscina Sampaio ([email protected]) on 2019-01-25T17:30:27Z No. of bitstreams: 1 LAROCCA,T.F. Assessment of syndecan-4...2018.pdf: 10166331 bytes, checksum: 0c3c0d4a7677f38a2fd443a1fc5f6d95 (MD5)Approved for entry into archive by Ana Maria Fiscina Sampaio ([email protected]) on 2019-01-25T17:58:58Z (GMT) No. of bitstreams: 1 LAROCCA,T.F. Assessment of syndecan-4...2018.pdf: 10166331 bytes, checksum: 0c3c0d4a7677f38a2fd443a1fc5f6d95 (MD5)Made available in DSpace on 2019-01-25T17:58:58Z (GMT). No. of bitstreams: 1 LAROCCA,T.F. Assessment of syndecan-4...2018.pdf: 10166331 bytes, checksum: 0c3c0d4a7677f38a2fd443a1fc5f6d95 (MD5) Previous issue date: 2018National Council for Research (CNPq), Research Foundation of Bahia State (FAPESB), and Funding Authority for Studies and Projects (FINEP).Hospital São Rafael. Centro de Biotecnologia e Terapia Celular. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.Hospital São Rafael. Centro de Biotecnologia e Terapia Celular. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.Hospital São Rafael. Centro de Biotecnologia e Terapia Celular. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.Hospital São Rafael. Centro de Biotecnologia e Terapia Celular. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.Hospital São Rafael. Centro de Biotecnologia e Terapia Celular. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.Hospital São Rafael. Centro de Biotecnologia e Terapia Celular. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.Hospital São Rafael. Centro de Biotecnologia e Terapia Celular. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil / Universidade federal da Bahia. Salvador, BA, Brasil.Messejana Hospital. Fortaleza, CE, Brasil.Messejana Hospital. Fortaleza, CE, Brasil.Hospital São Rafael. Centro de Biotecnologia e Terapia Celular. Salvador, BA, Brasil.Hospital São Rafael. Centro de Biotecnologia e Terapia Celular. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.Chronic Chagas cardiomyopathy (CCC) is characterized by the presence of a multifocal inflammatory response and myocardial damage, leading to fibrosis, arrhythmias and ventricular dysfunction. The expression of syndecan-4, a transmembrane proteoglycan, was previously found to be increased in the hearts of mice chronically infected with Trypanosoma cruzi. The possible involvement of syndecan-4 in the disease pathogenesis, however, remains unknown. Here we evaluated the pattern of expression of syndecan-4 in the heart tissue of T. cruzi infected mice and subjects with Chagas cardiomyopathy, correlating with the degree of inflammation and fibrosis

Image-guided percutaneous intralesional administration of mesenchymal stromal cells in subjects with chronic complete spinal cord injury: a pilot study

Submitted by Ana Maria Fiscina Sampaio ([email protected]) on 2017-08-16T13:31:50Z No. of bitstreams: 1 Larocca TF Image-guided....pdf: 387218 bytes, checksum: 3e5d59f868cf7e153f1aa904be8b2251 (MD5)Approved for entry into archive by Ana Maria Fiscina Sampaio ([email protected]) on 2017-08-16T13:45:57Z (GMT) No. of bitstreams: 1 Larocca TF Image-guided....pdf: 387218 bytes, checksum: 3e5d59f868cf7e153f1aa904be8b2251 (MD5)Made available in DSpace on 2017-08-16T13:45:57Z (GMT). No. of bitstreams: 1 Larocca TF Image-guided....pdf: 387218 bytes, checksum: 3e5d59f868cf7e153f1aa904be8b2251 (MD5) Previous issue date: 2017Brazilian Development Bank (BNDES).Hospital São Rafael. Center for Biotechnology and Cell Therapy. Salvador, BA, Brazil / Hospital São Rafael. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, BrasilHospital São Rafael. Center for Biotechnology and Cell Therapy. Salvador, BA, Brazil / Hospital São Rafael. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, BrasilHospital São Rafael. Center for Biotechnology and Cell Therapy. Salvador, BA, Brazil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil / National Institute of Science andTechnology for Regenerative Medicine. Rio de Janeiro, RJ, BrazilHospital São Rafael. Salvador, BA, BrasilHospital São Rafael. Center for Biotechnology and Cell Therapy. Salvador, BA, Brazil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil / University of Bahia. Faculty of Pharmacy. Salvador, BA, BrazilHospital São Rafael. Salvador, BA, BrasilHospital São Rafael. Center for Biotechnology and Cell Therapy. Salvador, BA, Brazil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, BrasilHospital São Rafael. Center for Biotechnology and Cell Therapy. Salvador, BA, Brazil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, BrasilHospital São Rafael. Center for Biotechnology and Cell Therapy. Salvador, BA, Brazil / Hospital São Rafael. Salvador, BA, BrasilHospital São Rafael. Center for Biotechnology and Cell Therapy. Salvador, BA, BrazilHospital São Rafael. Center for Biotechnology and Cell Therapy. Salvador, BA, BrazilHospital São Rafael. Salvador, BA, BrasilHospital São Rafael. Center for Biotechnology and Cell Therapy. Salvador, BA, Brazil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil / National Institute of Science andTechnology for Regenerative Medicine. Rio de Janeiro, RJ, BrazilHospital São Rafael. Center for Biotechnology and Cell Therapy. Salvador, BA, Brazil / National Institute of Science andTechnology for Regenerative Medicine. Rio de Janeiro, RJ, BrazilThe potential of cell therapies to improve neurological function in subjects with spinal cord injury (SCI) is currently under investigation. In this context, the choice of cell type, dose, route and administration regimen are key factors. Mesenchymal stromal cells (MSCs) can be easily obtained, expanded and are suitable for autologous transplantation. Here we conducted a pilot study that evaluated safety, feasibility and potential efficacy of intralesional MSCs transplantation performed through image-guided percutaneous injection, in subjects with chronic complete SCI. Methods. Five subjects with chronic traumatic SCI (>6 months), at thoracic level, classified as American Spinal Cord Injury Association impairment scale (AIS) grade A, complete injury, were included. Somatosensory evoked potentials (SSEP), spinal magnetic resonance imaging (MRI) and urodynamics were assessed before and after treatment. Autologous MSCs were injected directly into the lesion site through percutaneous injection guided by computerized tomography (CT). Results. Tomography-guided percutaneous cell transplantation was a safe procedure without adverse effects. All subjects displayed improvements in spinal cord independence measure (SCIM) scores and functional independence measure (FIM), mainly due to improvements in bowel movements and regularity. Three subjects showed improved sensitivity to tactile stimulation.Two subjects improved AIS grade to B, incomplete injury, although this was sustained in only one of them during the study follow-up. Conclusion. Autologous bone marrow MSC transplantation, performed through CT-guided percutaneous injection, was shown to be safe and feasible. Further studies are required to demonstrate efficacy of this therapeutic scheme

Lack of association between serum syndecan-4, myocardial fibrosis and ventricular dysfunction in subjects with chronic Chagas disease

<div><p>Background</p><p>Syndecan-4 is a transmembrane glycoprotein associated with inflammation and fibrosis. Increased syndecan-4 levels were previously detected after acute myocardial infarction and in subjects with heart failure. However, the levels of syndecan-4 in subjects with Chagas disease have not so far been investigated. The aim of this study was to investigate the potential role of serum sydencan-4 as a novel biomarker for myocardial fibrosis and cardiac dysfunction in subjects with Chagas disease.</p><p>Methods</p><p>This study comprised subjects with Chagas disease (n = 56), being 14 (25%) with the indeterminate form, 16 (29%) with the cardiac form without ventricular dysfunction, and 26 (46%) with the cardiac form with ventricular dysfunction.</p><p>Results</p><p>Syndecan-4 serum concentrations did not correlate with presence or absence of myocardial fibrosis (P = 0.386) nor disease severity in subjects with Chagas disease (P = 0.918). Additionally, no correlation was found either between the degree of myocardial fibrosis and serum syndecan-4 [r = 0.08; P = 0.567] or between left ventricular ejection fraction and syndecan-4 [r = 0.02; P = 0.864]. In contrast, NT-proBNP levels correlated with ejection fraction and myocardial fibrosis.</p><p>Conclusions</p><p>Our results demonstrate the lack of correlations between serum syndecan-4, myocardial fibrosis and cardiac dysfunction in subjects with Chagas disease. Further studies are required to show if syndecan-4 concentrations can be marker for prognosis assessment or disease progression.</p></div